Duvarizumab Injection must be administered under the supervision and operation of a medical professional by intravenous infusion of the drug for treatment. This drug is a human immunoglobulin monoclonal antibody. Patients with stage III non-small cell lung cancer that cannot be removed by surgery may use this drug under the supervision of a physician if they are receiving platinum-based chemotherapy with concurrent radiation therapy and if they are not experiencing disease progression. The mode of administration is by intravenous infusion, and each infusion takes longer than one hour. The use of this drug may cause a number of adverse reactions, the most common of which are cough, physical fatigue, non-infectious or radiation pneumonitis, dyspnea, upper respiratory tract infections, and skin rashes. Note that the drug must be contraindicated in people who are allergic to it. The use of Duvarizumab Injection is regulated in strict compliance with medical advice and should never be abused.